These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 20302959)

  • 1. Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
    Le RQ; Bevans M; Savani BN; Mitchell SA; Stringaris K; Koklanaris E; Barrett AJ
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1162-70. PubMed ID: 20302959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.
    Bevans MF; Mitchell SA; Barrett JA; Bishop MR; Childs R; Fowler D; Krumlauf M; Prince P; Shelburne N; Wehrlen L; Yang L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):387-95. PubMed ID: 24355521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes in survivors of childhood hematologic malignancies with hematopoietic stem cell transplant.
    Yen HJ; Eissa HM; Bhatt NS; Huang S; Ehrhardt MJ; Bhakta N; Ness KK; Krull KR; Srivastava DK; Robison LL; Hudson MM; Huang IC
    Blood; 2020 May; 135(21):1847-1858. PubMed ID: 32243495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health status, late effects and long-term survivorship of allogeneic bone marrow transplantation: a retrospective study.
    Gifford G; Sim J; Horne A; Ma D
    Intern Med J; 2014 Feb; 44(2):139-47. PubMed ID: 24320824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-Versus-Host-Disease and Health-Related Quality of Life in Young Long-term Survivors of Cancer and Allogeneic Hematopoietic Stem Cell Transplantation.
    Diep PP; Rueegg CS; Burman MM; Brinch L; Bø K; Fosså K; Landrø L; Loge JH; Lund MB; Massey RJ; Myrdal OH; Pathak M; Rimstad L; Tanem KE; Tjønnfjord GE; Aaløkken TM; Ruud E
    J Adolesc Young Adult Oncol; 2023 Feb; 12(1):66-75. PubMed ID: 35544321
    [No Abstract]   [Full Text] [Related]  

  • 6. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.
    Rovó A; Daikeler T; Halter J; Heim D; Tsakiris DA; Stern M; Waltimo T; Studt JD; Tyndall A; Gratwohl A; Tichelli A
    Haematologica; 2011 Jan; 96(1):150-5. PubMed ID: 20851864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
    Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
    Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
    Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of Life, Physical Functioning, and Psychological Distress of Older Adults Undergoing Hematopoietic Stem Cell Transplantation.
    Newcomb R; Johnson PC; Cronin K; Choe JJ; Holmbeck K; Nabily A; Lark P; Rabideau DJ; DeFilipp Z; Chen YB; El-Jawahri A
    Transplant Cell Ther; 2023 Jun; 29(6):387.e1-387.e7. PubMed ID: 36958693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation.
    Inaba H; Yang J; Kaste SC; Hartford CM; Motosue MS; Chemaitilly W; Triplett BM; Shook DR; Pui CH; Leung W
    J Clin Oncol; 2012 Nov; 30(32):3991-7. PubMed ID: 23032628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of post traumatic growth in allogeneic hematopoietic stem cell transplantation survivors: a cross-sectional survey.
    McErlean G; Tapp C; Brice L; Gilroy N; Kabir M; Greenwood M; Larsen SR; Moore J; Gottlieb D; Hertzberg M; Brown L; Hogg M; Huang G; Ward C; Kerridge I
    BMC Psychol; 2023 Aug; 11(1):235. PubMed ID: 37587508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fear of cancer recurrence following allogeneic haematopoietic stem cell transplantation (HSCT) for haematological malignancy: A cross-sectional study.
    Brice L; McErlean G; Donovan C; Tapp C; Gilroy N; Kabir M; Greenwood M; Larsen SR; Moore J; Gottlieb D; Hertzberg M; Brown L; Hogg M; Huang G; Tan J; Ward C; Kerridge I
    Eur J Oncol Nurs; 2020 Dec; 49():101845. PubMed ID: 33128994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol.
    Bevans MF; Mitchell SA; Barrett AJ; Bishop M; Childs R; Fowler D; Krumlauf M; Prince P; Shelburne N; Wehrlen L
    Health Qual Life Outcomes; 2011 Apr; 9():24. PubMed ID: 21496339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Day +100 Platelet Count Predicts Survival After Allogeneic Hematopoietic Stem-Cell Transplantation in Children With Hematologic Malignancies.
    Moneib H; Hafez H; Abdalla A; Hassanain O; Lehmann L; Haddad AE
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e221-e227. PubMed ID: 30846344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation.
    Inaba H; Yang J; Pan J; Stokes DC; Krasin MJ; Srinivasan A; Hartford CM; Pui CH; Leung W
    Cancer; 2010 Apr; 116(8):2020-30. PubMed ID: 20186702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.